Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

152.37 -1.27 (-0.83%)

Streaming Delayed Price Updated: 12:43 PM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	93,726
Open	153.76
Bid (Size)	152.08 (100)
Ask (Size)	152.47 (200)
Prev. Close	153.64
Today's Range	151.75 - 154.22
52wk Range	75.56 - 158.56
Shares Outstanding	47,190,970
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗

December 01, 2025

These drugmakers are poised to profit from their innovative engines.

Via The Motley Fool

Performance

YTD	+74.5%	+74.5%
1 Month	+1.3%	+1.3%
3 Month	+31.3%	+31.3%
6 Month	+48.6%	+48.6%
1 Year	+73.2%	+73.2%

More News

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Where Axsome Therapeutics Stands With Analysts ↗

August 04, 2025

Via Benzinga

Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Axsome Therapeutics to Participate in Upcoming Investor Conferences

November 20, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM

November 10, 2025

From Pomerantz LLP

Via GlobeNewswire

2 Monster Stocks in the Making ↗

November 10, 2025

Via The Motley Fool

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

November 06, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 03, 2025

Via Chartmill

Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Uncovering Potential: Axsome Therapeutics's Earnings Preview ↗

October 31, 2025

Via Benzinga

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 24, 2025

From Halper Sadeh LLC

Via Business Wire

Axsome Therapeutics to Participate in Upcoming Investor Conferences

October 22, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

October 09, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

October 07, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗

September 30, 2025

Via The Motley Fool

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

Via Investor's Business Daily

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

September 17, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗

September 04, 2025

Via The Motley Fool

A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts ↗

September 03, 2025

Via Benzinga

Axsome Therapeutics to Participate in Upcoming Investor Conferences

August 27, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years ↗

August 18, 2025

Via Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings ↗

August 05, 2025

Via Benzinga

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading ↗

August 04, 2025

Via Chartmill

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?

Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?

Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?

The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market

What is the current price of Axsome Therapeutics, Inc. - Common Stock?

The current price of Axsome Therapeutics, Inc. - Common Stock is 152.37

When was Axsome Therapeutics, Inc. - Common Stock last traded?

The last trade of Axsome Therapeutics, Inc. - Common Stock was at 12/26/25 12:43 PM ET

What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?

The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 7.19B

How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?

Axsome Therapeutics, Inc. - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.